Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 6 of 9 · 415 articles
This meta-analysis suggests people with IBD—especially those with Crohn’s disease—have a modestly increased risk of stroke. That makes cardiovascular risk assessment and prevention potentially more important for people...
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
A CE mark under the EU IVDR means a new non-invasive test aimed at identifying dietary triggers for people with UC or Crohn’s may become available in Europe. Tests like this could affect how some patients and clinicians...
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original...
A new CE-marked food-intolerance diagnostic could give people with Crohn’s or UC a non-invasive tool to explore dietary triggers alongside clinical care. Regulatory certification means the products met EU safety and...
A predictive model for temporary stoma could influence surgical planning for people with Crohn’s disease, helping tailor decisions and expectations around intestinal resection.
Cure8 could only read part of this source from appliedclinicaltrialsonline.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Crohn's disease, and Inflammatory...
Researchers and clinicians studying Crohn’s disease want to understand whether distinct patient subgroups exist that could affect outcomes or responses. Identifying subpopulations can guide future research into...
Based on the title and source metadata, this appears to be a low information aggregator related to Inflammatory bowel disease and Research and clinical trials. The original article is from israel21c.org.
Cure8 found this source from business-standard.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.
The Phase 2b results suggest the investigational TL1A drug duvakitug improved clinical and endoscopic outcomes versus placebo in both ulcerative colitis and Crohn’s disease, which could expand future treatment options if...
The article reports new phase 2 trial data for duvakitug, an experimental anti‑TL1A treatment for ulcerative colitis and Crohn’s disease, which helps compare it to rival candidates and shapes upcoming phase 3 plans.
This reports Phase 2b trial results for duvakitug showing improved remission and endoscopic response versus placebo in UC and CD—early evidence that could lead to a new treatment option if later trials confirm benefit...
Changes in the therapeutics market can affect availability, pricing, and access to Crohn’s treatments. Growth in biosimilars and new drug approvals may influence what options become more widely available.
The study explores whether larger spleen size might play a causal role in the risk of ulcerative colitis or Crohn’s disease, using genetic data to reduce confounding. If a causal link exists, spleen volume could be a...
Cure8 found this source from finance.yahoo.com, but the page could not be read reliably yet. It is tagged for Ustekinumab, Biosimilars, and IL-12/23 inhibitor. Open the original article for the full details.
If approved, Tremfya SC induction could provide a fully subcutaneous induction and maintenance option for people with moderately to severely active ulcerative colitis, which may be more convenient than IV induction.
New Phase 2b data were presented for duvakitug, an investigational antibody for UC and Crohn’s disease; people with IBD may see this as a potential future treatment option if later trials are positive. The report focuses...
Cure8 found this source from rollingout.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
This press release reports phase 2 evidence that a new experimental antibody (duvakitug) showed clinical, endoscopic, and histologic improvements in both UC and Crohn’s disease, which could lead to a new treatment option...
A new antibody, duvakitug, showed higher remission/response rates than placebo in Phase 2b study data for both ulcerative colitis and Crohn’s disease, which could lead to a new treatment option if Phase 3 trials confirm...
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the...
People with Crohn's disease who have an ileostomy need reliable, noninvasive tools to monitor for postoperative small-bowel inflammation. This study suggests fecal calprotectin measured from ileostomy output may help...
Patients and clinicians following new, non‑immunosuppressive approaches to UC may be interested because MB310 is an oral live‑biotherapeutic designed to induce remission and is entering clinical testing.
A new ustekinumab biosimilar (SELARSDI) is now available in the U.S. for Crohn’s disease and ulcerative colitis, which may expand treatment options and affect access or cost for patients on biologic therapy.
The study suggests a surgical change—removing the mesentery during Crohn’s operations—may significantly reduce early recurrence in the intestinal lining, which could mean fewer repeat surgeries and hospital readmissions...
Cure8 found this source from businesswire.com, but the page could not be read reliably yet. It is tagged for Research and clinical trials. Open the original article for the full details.
This study maps what researchers have been publishing about Crohn's disease in children over the past decade, highlighting major topics, influential papers, and active authors/institutions.
Some people with Crohn’s have ongoing GI symptoms despite little visible inflammation. This study suggests the gut microbiome—particularly sulfur-producing bacteria—may be a reason, and diet could be a potential target...
The article summarizes a commercial market report that lists current and upcoming Crohn's disease treatments, trial results, and a biosimilar approval — information patients may see reflected in treatment availability,...
This is early-stage research about combining antibody targets (α4β7 and TL1A) for IBD; if validated in humans, combination biologics could offer improved effectiveness or dosing convenience.
Cure8 found this source from tipranks.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...
A surgical technique (mesentery removal) reported in an international randomized trial lowered early endoscopic recurrence after Crohn’s surgery. If validated more widely, it could reduce repeat operations and hospital...
Arthralgia and other extraintestinal symptoms may signal higher risk of developing peripheral arthritis in people with Crohn disease. Recognizing early joint pain could prompt closer monitoring or earlier rheumatology...
Early Phase 2 data suggest VTX958 may improve endoscopic healing and lower inflammatory markers in Crohn’s disease, outcomes that matter for long-term disease control. The report also notes the trial missed its primary...
This reports Phase 2 clinical data for an oral TYK2 inhibitor (VTX958) in Crohn’s disease — a potential new oral treatment approach. The drug showed meaningful endoscopic improvements and reductions in inflammatory...
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.
Cure8 found this source from gut.bmj.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
This announcement signals growing clinical and preclinical data for obefazimod, an investigational IBD drug; it includes a preclinical report on anti-fibrotic activity, a complication important in Crohn’s disease.
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from alphagalileo.org.
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from miragenews.com.
If you have IBD or are at risk for colorectal disease, clinicians at the conference highlighted that these conditions are being seen more often and that treatment approaches have shifted toward personalized medicine and...
Cure8 found this source from academic.oup.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Research and clinical trials. Open the original article for the full details.
The article reports rising colorectal disease and IBD rates and describes modern shifts in treatment—topics that can affect screening, treatment options, and specialist care access for people with IBD or colorectal...
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. Open the original article...
Longer-term data help patients and clinicians understand whether an initial response to a new biologic (mirikizumab) is likely to last and whether safety findings remain acceptable over two years.
A validated AI biomarker that predicts which IBD treatments are likely to work could reduce trial-and-error in treatment choices, potentially shortening time to effective therapy for people with Crohn's disease or...
